Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers.
Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers.
复制标题
DOI:
10.3390/vaccines8040681
复制
发表时间:
2020-11-13
期刊:
影响因子:
7.8
通讯作者:
Biberfeld G
中科院分区:
文献类型:
--
作者:
Joachim A;Msafiri F;Onkar S;Munseri P;Aboud S;Lyamuya EF;Bakari M;Billings E;Robb ML;Wahren B;Mhalu FS;Sandström E;Rao M;Nilsson C;Biberfeld G
We evaluated antibody responses to the human immunodeficiency virus (HIV) envelope variable regions 1 and 2 (V1V2) in 29 vaccinees who had received three HIV-1 DNA immunizations and two HIV-modified vaccinia virus Ankara (MVA) boosts in the phase I/II HIVIS03 vaccine trial. Twenty vaccinees received a third HIV-MVA boost after three years in the HIVIS06 trial. IgG and IgG antibody subclasses to gp70V1V2 proteins of HIV-1 A244, CN54, Consensus C, and Case A2 were analysed using an enzyme-linked immunosorbent assay (ELISA). Cyclic V2 peptides of A244, Consensus C, and MN were used in a surface plasmon resonance (SPR) assay. Four weeks after the second HIV-MVA, anti-V1V2 IgG antibodies to A244 were detected in 97% of HIVIS03 vaccinees, in 75% three years later, and in 95% after the third HIV-MVA. Anti-CN54 V1V2 IgG was detectable in 48% four weeks after the second HIV-MVA. The SPR data supported the findings. The IgG response was predominantly IgG1. Four weeks after the second HIV-MVA, 85% of vaccinees had IgG1 antibodies to V1V2 A244, which persisted in 25% for three-years. IgG3 and IgG4 antibodies to V1V2 A244 were rare. In conclusion, the HIV-DNA/MVA vaccine regimen induced durable V1V2 IgG antibody responses in a high proportion of vaccinees.
登录
查看更多内容
影响因子:
56.3
作者:
Gray, Glenda E.;Allen, Mai;Moodie, Zoe;Churchyard, Gavin;Bekker, Linda-Gail;Nchabeleng, Maphoshane;Mlisana, Koleka;Metch, Barbara;de Bruyn, Guy;Latka, Mary H.;Roux, Surita;Mathebula, Matsontso;Naicker, Nivashnee;Ducar, Constance;Carter, Donald K.;Puren, Adrien;Eaton, Niles;McElrath, M. Julie;Robertson, Michael;Corey, Lawrence;Kublin, James G.
通讯作者:
Kublin, James G.
影响因子:
3.7
作者:
Buchbinder SP;Grunenberg NA;Sanchez BJ;Seaton KE;Ferrari G;Moody MA;Frahm N;Montefiori DC;Hay CM;Goepfert PA;Baden LR;Robinson HL;Yu X;Gilbert PB;McElrath MJ;Huang Y;Tomaras GD;HIV Vaccine Trials Network (HVTN) 094 Study Group
通讯作者:
HIV Vaccine Trials Network (HVTN) 094 Study Group
影响因子:
3.7
作者:
Joachim A;Nilsson C;Aboud S;Bakari M;Lyamuya EF;Robb ML;Marovich MA;Earl P;Moss B;Ochsenbauer C;Wahren B;Mhalu F;Sandström E;Biberfeld G;Ferrari G;Polonis VR
通讯作者:
Polonis VR
影响因子:
--
作者:
Natvig, J B;Kunkel, H G
通讯作者:
Kunkel, H G
DOI:
10.1093/infdis/jis033
发表时间:
2012-04-01
期刊:
The Journal of infectious diseases
影响因子:
--
作者:
Kam YW;Simarmata D;Chow A;Her Z;Teng TS;Ong EK;Rénia L;Leo YS;Ng LF
通讯作者:
Ng LF